Back to search

Article

Reversing TGF-β1-induced fibrotic phenotype in human lung fibroblasts using a PROTAC tool derived from an indoline-based HDAC6 inhibitor

2025-05-21

Abstract excerpt

Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating interstitial lung disease characterized by limited therapeutic options, with only two FDA-approved palliative agents currently available. Given its poor prognosis and the high incidence of lung transplantation, there is a pressing need to develop innovative and effective therapeutics. Histone deacetylase 6 (HDAC6) has been identified as a key dr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4b71bb2d-f208-51f8-9645-4407a1c56ae5
DOI
10.1016/j.ejmcr.2025.100276
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Reversing TGF-β1-induced fibrotic phenotype in human lung fibroblasts using a PROTAC tool derived from an indoline-based HDAC6 inhibitorDOI 10.1016/j.ejmcr.2025.100276
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective InhibitorsSemantic proximity
Developing potent PROTACs tools for selective degradation of HDAC6 proteinSemantic proximity
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic OptionSemantic proximity
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo TractabilitySemantic proximity
Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settingsSemantic proximity
Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosisSemantic proximity
Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosisSemantic proximity
Tankyrase inhibition demonstrates anti-fibrotic effects in preclinical pulmonary fibrosis modelsSemantic proximity
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACsSemantic proximity
Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical ApplicationsSemantic proximity
PROTACs: great opportunities for academia and industrySemantic proximity
Select a neighboring publication to make it the new centre.